Alcohol (ethanol) is a small water-soluble molecule that acts as a central nervous system depressant, the same pharmacological class as benzodiazepines and barbiturates. It crosses the blood-brain barrier within minutes of ingestion and produces its effects by potentiating GABA-A receptors (inhibitory) and inhibiting NMDA glutamate receptors (excitatory). At low doses this presents as relaxation, lowered social inhibition, and mild euphoria. At higher doses it produces sedation, motor and cognitive impairment, and memory disruption.
Ethanol is metabolised in the liver, primarily by alcohol dehydrogenase to acetaldehyde, then by aldehyde dehydrogenase to acetate. Acetaldehyde is the toxic and carcinogenic intermediate responsible for much of alcohol's downstream damage. A standard drink contains roughly 14g of ethanol: a 12oz beer at 5%, a 5oz glass of wine at 12%, or a 1.5oz shot of spirits at 40%.
Deep-dive
Acute neuropharmacology. Ethanol potentiates GABA-A receptors, the same inhibitory channels targeted by benzodiazepines and barbiturates, producing anxiolysis, sedation, and disinhibition. It simultaneously inhibits NMDA glutamate receptors, the excitatory channels involved in learning and memory consolidation, which is the mechanism behind alcohol-induced memory impairment and blackouts at higher blood alcohol concentrations. Ethanol also indirectly raises dopamine in the mesolimbic pathway and modulates serotonin, endogenous opioid, and glycine signalling.
Chronic adaptation and withdrawal. With sustained exposure, the brain downregulates GABA receptors and upregulates NMDA receptors to compensate. When alcohol is removed, the resulting imbalance produces withdrawal: anxiety, tremor, and at severe levels, seizures and delirium tremens. Alcohol withdrawal is one of the few drug withdrawal syndromes that can be fatal without medical management.
Mortality and the J-curve. Earlier observational studies showed light-to-moderate drinkers having lower all-cause mortality than non-drinkers, particularly for cardiovascular outcomes, producing a J-shaped curve. More recent Mendelian randomization analyses, which use genetic variants predicting alcohol intake to reduce confounding, have not replicated the protective J-shape. In a 2024 analysis of 278,093 UK Biobank participants, genetically predicted alcohol consumption was associated with increased mortality from all leading causes, with no evidence for a protective threshold. The current interpretation is that earlier J-curve findings reflected confounding from former drinkers and sick abstainers being grouped with lifetime non-drinkers in the reference category.
Cancer. Ethanol's metabolite acetaldehyde is classified as a Group 1 carcinogen by the IARC. A 2023 meta-analysis of 139 cohort studies found dose-dependent associations with multiple cancers. Light drinking (under one drink per day) was significantly associated with esophageal cancer (RR 1.39), colorectal cancer (RR 1.04), prostate cancer in men (RR 1.05), and breast cancer in women (RR 1.05). Dose-response analysis across 23 cancer types showed heavy drinkers had roughly 5.1x the risk of oral and pharyngeal cancer, 5.0x esophageal squamous cell carcinoma, 2.7x laryngeal, 1.6x breast, and 1.4x colorectal cancer. No safe lower threshold has been established for alcohol-related cancer risk.
Liver. An autopsy series of 210 males found no significant rise in alcoholic liver disease features below a daily intake of 40g over 25 years. Intake of 40-80g/day raised the prevalence of fatty liver from 12% to 47% and significantly increased cirrhosis risk. In women, the threshold is approximately half, around 20g/day. The progression runs from steatosis (reversible) to alcoholic hepatitis (partially reversible) to cirrhosis (not reversible). Obesity, viral hepatitis, and smoking accelerate progression.
Blood pressure and hypertension. A 2023 dose-response meta-analysis found a substantially linear positive association between alcohol intake and blood pressure with no threshold effect. Average systolic BP was 1.25 mmHg higher at 12g/day and 4.90 mmHg higher at 48g/day compared to no consumption. A follow-up meta-analysis on hypertension incidence showed risk ratios of 1.11, 1.22, and 1.33 at 24, 36, and 48 g/day respectively, using 12g/day as the reference.
Sleep architecture. A 2024 meta-analysis of 27 studies found dose-dependent disruption of sleep architecture. Even low doses (≤0.5 g/kg, approximately two standard drinks) reduced REM sleep duration and delayed REM onset. Higher doses (≥0.85 g/kg) shortened sleep onset latency and increased slow-wave sleep in the first half of the night, followed by fragmented sleep and rebound wakefulness in the second half as ethanol metabolises out. Total REM sleep is reduced at moderate and high doses across studies.
Brain structure. An imaging study of 36,678 UK Biobank participants found dose-dependent negative associations between alcohol intake and global grey matter volume, regional grey matter volumes, and white matter microstructure. The associations were apparent at one to two daily units and scaled with intake. A separate 25,378-participant UK Biobank analysis reported similar findings, with no observed safe threshold for brain structural measures.
Sex differences. Women reach higher blood alcohol concentrations than men from the same dose, even after adjusting for body weight. Three mechanisms contribute: women have a higher body fat percentage and lower total body water, producing a smaller volume of distribution; women have lower gastric alcohol dehydrogenase activity, reducing first-pass metabolism; and despite faster alcohol clearance per kg of lean body mass, the higher peak BAC produces greater cumulative exposure per drink. The liver disease threshold in women is roughly half the male threshold. The menstrual cycle has not been shown to meaningfully affect alcohol pharmacokinetics.
Alcohol and breast cancer mechanism. In human breast cancer cell lines, ethanol produced a dose-dependent 10-15 fold increase in liganded oestrogen receptor (ER-α) transcriptional activity, partly through downregulation of BRCA1 and partly through modest increases in ER-α expression. Alcohol-associated breast cancers are predominantly ER-positive and PR-positive. Increased circulating oestrogen levels with alcohol intake have been documented in both pre- and postmenopausal women, and are the leading proposed mechanism behind the consistent dose-response relationship between alcohol and breast cancer.
ALDH2 deficiency. Approximately 30-50% of people of East Asian descent carry a variant of the ALDH2 gene that severely reduces aldehyde dehydrogenase activity. This produces facial flushing, nausea, and tachycardia with drinking, and substantially elevated acetaldehyde exposure. Carriers have multifold higher rates of esophageal cancer for any given alcohol intake.
Older adults. Total body water and liver volume both decline with age, so the same dose produces higher BAC. The aging brain is also more sensitive to acute and chronic alcohol effects, and the risks of falls, drug interactions (particularly with benzodiazepines, opioids, and sedating antihistamines), and cognitive impairment all rise. Most guideline bodies recommend lower limits over age 65.
Limitations of the evidence. Most alcohol research is observational and subject to confounding, reverse causation (people stop drinking when sick), and reporting bias. Mendelian randomization addresses some of these but is limited by the precision of genetic instruments at low intakes. Randomised long-term trials at meaningful doses are not ethical. Individual variation in response is large and driven by genetics, body composition, drinking pattern (regular versus binge), liver health, and co-ingested substances. Average weekly intake numbers obscure the very different harm profiles of one drink nightly versus seven in a single session.
Dosage:
- A standard drink is roughly 14g of pure ethanol: a 12oz beer at 5%, a 5oz glass of wine at 12%, or a 1.5oz shot of spirits at 40%
- US dietary guidelines define moderate drinking as up to 2 drinks/day for men and 1 drink/day for women. UK guidelines recommend no more than 14 units/week (around 112g) for both sexes, spread over at least 3 days
- Liver disease risk rises sharply above 40g/day (≈3 drinks) in men and 20g/day (≈1.5 drinks) in women, sustained over years
- Cancer and brain volume signals appear from low intakes (one drink per day or less) with no established threshold below which risk is zero
- Blood pressure rises linearly with intake from the first drink
- Peak BAC is reached 30-90 minutes after ingestion. Food in the stomach slows absorption and lowers peak BAC by approximately 30-50%
- Average elimination rate is roughly 0.015% BAC per hour, or one standard drink per 60-90 minutes
- Binge drinking is defined as 5+ drinks (men) or 4+ drinks (women) in 2 hours, producing BAC ≥0.08%. This pattern carries acute cardiovascular and injury risks distinct from average daily intake
- Drinking within 3-4 hours of bed produces measurable REM suppression and second-half-of-night sleep fragmentation even at low doses
- Women reach BACs 30-40% higher than men from the same weight-adjusted dose. Adjusting intake downward roughly halves the effective dose
- Older adults reach higher BACs from the same dose due to reduced body water and slower clearance
Here's what you can expect:
At one to two drinks (BAC roughly 0.02-0.05%), most people experience relaxation, mild euphoria, and lowered social inhibition within 20-40 minutes. Reaction time and fine motor coordination are measurably impaired even when subjective impairment is mild. Sleep that night will have reduced REM and more fragmented second-half sleep, even if sleep onset feels easier.
At three to four drinks (BAC roughly 0.06-0.10%), there is clear impairment of judgement, motor control, and memory encoding. Heart rate rises, flushing is common. Sleep is significantly disrupted with rebound wakefulness in the early morning hours.
At five or more drinks in a single session (BAC ≥0.15%), substantial cognitive and motor impairment, suppressed behavioural inhibition, and meaningful risk of memory blackout. Hangover symptoms the next day reflect acetaldehyde exposure, dehydration, inflammation, and disrupted sleep.
With chronic daily use at any level, gradual changes accumulate: reductions in brain grey matter volume, rising blood pressure, hepatic fat accumulation, and increased tolerance requiring higher doses to produce the same subjective effect. These changes are typically not noticeable week-to-week.
With sustained abstinence, sleep quality, mood, and energy typically improve within 2-4 weeks. Elevated liver enzymes begin to normalise within weeks. Blood pressure typically drops within 1-2 months. Reversibility of brain volume changes is partial.
Side effects & risks:
- Cancer: dose-dependent increased risk of oral, pharyngeal, laryngeal, esophageal, colorectal, liver, and breast cancers. No safe lower threshold established
- Liver disease: progresses from steatosis (reversible) to alcoholic hepatitis (partially reversible) to cirrhosis (not reversible). Thresholds approximately 40g/day in men and 20g/day in women sustained over years. Obesity, viral hepatitis, and smoking accelerate progression
- Hypertension: linear dose-response with no threshold
- Sleep disruption: REM suppression and fragmented second-half-of-night sleep at all doses
- Brain volume loss: dose-dependent reductions in grey matter and white matter integrity on MRI, starting at one to two daily drinks in middle-aged adults
- Mood and anxiety: acute anxiolysis followed by rebound anxiety. Chronic use is associated with worsened baseline mood and increased anxiety and depression risk
- Dependence: roughly 10-15% lifetime prevalence of alcohol use disorder among regular drinkers. Withdrawal can be medically serious. Daily drinkers, particularly at higher intakes, should not stop abruptly without medical guidance due to seizure risk
- Medication interactions: potentiates benzodiazepines, opioids, sedating antihistamines, sleep medications, and many antidepressants. Co-ingestion with benzodiazepines or opioids is a leading cause of accidental overdose. Severe hepatotoxicity risk with acetaminophen at higher doses. Disulfiram-like reactions with metronidazole and certain other antibiotics
- Pregnancy: crosses placenta freely. Fetal alcohol spectrum disorders are a leading preventable cause of birth defects and developmental disability. No safe threshold has been established
- ALDH2 deficiency: in carriers (common in East Asian populations), accumulated acetaldehyde produces flushing, nausea, and substantially elevated cancer risk, particularly esophageal cancer
- Acute risks: impaired driving, falls, injury, drowning, alcohol poisoning, and arrhythmia. Disproportionate contributor to alcohol-attributable mortality, particularly in younger drinkers
Blood markers
GGT, ALT, AST, baseline if drinking regularly above light intakes (more than 5-7 drinks per week). GGT is the most alcohol-sensitive liver enzyme and rises before AST and ALT in early alcoholic liver injury. AST:ALT ratio above 2 is a classic pattern in alcoholic hepatitis. Recheck every 6-12 months with regular drinking, or 4 weeks into a sustained dry period to assess reversibility.
MCV (mean corpuscular volume), baseline. Chronically elevated MCV on a standard CBC is a consistent marker of regular alcohol exposure, reflecting direct toxic effects on red blood cell precursors. Normalises slowly over 2-3 months of abstinence.
Blood pressure, baseline and ongoing if drinking daily. Dose-response is linear with no threshold.
HDL and triglycerides on a standard lipid panel. Alcohol raises HDL and also raises triglycerides at higher intakes.
HbA1c and fasting glucose with regular drinking, given alcohol's effects on glucose regulation and insulin sensitivity, particularly when combined with the caloric load and sleep disruption.
CDT (carbohydrate-deficient transferrin) is the most specific blood marker for sustained heavy drinking, with a window of approximately 2-3 weeks. Used clinically when other markers are ambiguous.
For light or occasional drinking, no specific bloodwork is needed. For anyone drinking daily or more than 10-14 drinks per week, GGT plus MCV plus blood pressure gives a useful baseline.
Legal and widely available in most countries.
Made with Bullet